abstract |
The invention relates to a compound comprising an endothelin antagonist polypeptide homologous to at least 40% of an active endothelin peptide, constitutive of Et-1, Et-2, Et-3, SC, SA and SB, of the formula (I), as well as its pharmaceutically acceptable salts. |